<DOC>
	<DOCNO>NCT02159521</DOCNO>
	<brief_summary>To evaluate efficacy ultrasound accelerated thrombolysis use EkoSonic® Endovascular System standard infusion thrombolytic drug post-thrombotic syndrome chronic venous occlusion .</brief_summary>
	<brief_title>Treatment Chronic Deep Vein Thrombosis ( DVT ) Post-Thrombotic Syndrome ( PTS ) With EkoSonic Endovascular System</brief_title>
	<detailed_description>The study design evaluate safety efficacy ultrasound accelerated thrombolysis use EkoSonic® Endovascular System standard infusion thrombolytic drug PTS chronic DVT . Clinical effectiveness evaluate use standard measure severity post-thrombotic syndrome year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<criteria>Key Inclusion criterion : 1 . Male female ≥ 18 year age ≤ 75 year age . 2 . Proximal DVT ( iliac vein , common femoral vein , deep femoral vein , femoral vein ) objectively diagnose duplex image and/or venography ≥ 6 month prior study screen . 3 . Persistent chronic DVT cause restrictive flow , confirm imaging , within 60 day prior study procedure . 4 . Villalta score ≥8 affect limb within 30 day prior study procedure . 5 . Failed minimum 3 consecutive month conservative treatment ( therapeutic anticoagulation compression stocking ) accord complete Adherence Conservative Treatment Form . Key 1 . Treated mechanical thrombectomy within 2 week study thrombolysis procedure . 2 . Treated thrombolysis drug within 48 hour study thrombolytic procedure . 3 . Life expectancy less 1 year . 4 . Body Mass Index ( BMI ) &gt; 40 kg/m2 per Investigator 's discretion subject able tolerate procedure compliant postprocedure increase physical activity . 5 . No flow popliteal vein duplex image 6 . Isolated iliac vein thrombus . 7 . Thrombus extend ≥ 3 cm inferior vena cava ( IVC ) . If central venous occlusion , consider compute tomography ( CT ) magnetic resonance venography ( MRV ) . For subject bilateral DVT , recommend central imaging perform prior treatment evaluate status IVC . 8 . Active bleeding , recent ( &lt; 3 mo ) gastrointestinal ( GI ) bleeding , active peptic ulcer , severe liver dysfunction , bleed diathesis . 9 . Recent ( &lt; 3 mo ) internal eye surgery hemorrhagic retinopathy ; recent ( &lt; 10 day ) major surgery , cataract surgery , trauma , cardiopulmonary resuscitation ( CPR ) , obstetrical delivery , invasive procedure . 10 . History stroke intracranial/intraspinal bleed , tumor , vascular malformation , aneurysm . 11 . Active cancer ( metastatic , progressive , treat within last 6 month ) . Exception : subject nonmelanoma primary skin cancer eligible participate study . 12 . Hemoglobin &lt; 9.0 mg/dl within 24 hour prior procedure 13. International normalize ratio ( INR ) ≥ 1.5 ng/dl within 24 hour prior procedure 14 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 within 24 hour prior procedure . 15 . Creatinine outside normal range treat institution consider clinically significant Investigator . 16 . Uncontrolled hypertension , define systolic &gt; 175 mmHg diastolic &gt; 110 mmHg . 17 . Use clopidogrel , ticlopidine , thienopyridine antiplatelet drug within 7 day study procedure . 18 . In judgment clinician , subject high risk catastrophic bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>deep vein thrombosis</keyword>
	<keyword>post-thrombotic syndrome</keyword>
	<keyword>chronic deep vein thrombosis</keyword>
</DOC>